Key Insights

Highlights

Success Rate

83% trial completion

Treatment Research

20 treatments under study, led by Lacosamide

Research Leaders

17 sponsors active, led by ETH Zurich

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

9.1%

1 terminated out of 11 trials

Success Rate

83.3%

-3.3% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results83% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (7)
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Completed5
Active Not Recruiting2
Terminated1
Recruiting1
Unknown1
Not Yet Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (11)

Research Network

Common Treatments

  • Lacosamide1
  • Selfadministration Of Auricular Acupuncture Without Prosthesis1
  • Lidocaine Hydrochloride1
  • Axonflair Mediated Respons1
  • Inf Therapy1

Active Sponsors

  • ETH Zurich2
  • Dana-Farber Cancer Institute2
  • Danish Pain Research Center1
  • Erchonia Corporation1
  • Memorial Sloan Kettering Cancer Center1

Top Investigators

Related Conditions

  • Neuropathy Diabetic4
  • Neuropathy4
  • Pain3
  • Neuropathyperipheral3
  • Chemotherapyinduced Peripheral Neuropathy3

Activity Timeline